Linaxa M 1000mg/5mg Tablet XR is a combination oral antidiabetic medication containing Metformin hydrochloride 1000mg and Linagliptin 5mg in an extended-release formulation. It is indicated for the management of type 2 diabetes mellitus in adults to improve glycemic control when diet and exercise alone are insufficient. Metformin primarily acts by decreasing hepatic glucose production, enhancing insulin sensitivity, and improving peripheral glucose uptake, while Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels, thereby stimulating insulin release and suppressing glucagon secretion in a glucose-dependent manner. The extended-release formulation allows for once-daily dosing, promoting better patient adherence and minimizing gastrointestinal side effects commonly associated with immediate-release Metformin. Linaxa M should be used with caution in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Regular monitoring of blood glucose levels, renal function, and potential adverse effects is recommended during therapy. This combination therapy offers a complementary mechanism of action to achieve improved glycemic control with a reduced risk of hypoglycemia compared to some other antidiabetic agents. Linaxa M 1000mg/5mg Tablet XR should be prescribed as part of a comprehensive diabetes management plan including diet, exercise, and lifestyle modifications.